Drug price controls review criticised
A review of UK drug price controls has been criticised by the Association of the British Pharmaceutical Industry (APBI).
The UK pharmaceutical price regulation scheme (PPRS) was originally planned for 2010, but an early move could have a negative impact on those in pharmaceutical company sales jobs.
PPRS sets the limit to the increases companies are allowed to make to treatments sold to the NHS.
However, ABPI president Nigel Brooksby has claimed that the decision undermines the industries confidence in the UK government to support domestic investment.
"The government's decision dented business confidence and the reaction from our global head offices moved the matter beyond the UK, as they began to question the integrity of the UK investment environment," he added.
Many in senior pharmaceutical sales jobs are likely to agree that the announcement to bring the review forward by two years could damage business and effect sales recruitment plans.
It is also poorly timed, as the European Commission prepares funding for its first set of projects to boost to pharmaceutical medicines development in Europe through the Innovative Medicines Initiative (IMI).
Filed: 02-05-2008
|